Market capitalization | $1.11b |
Enterprise Value | $1.21b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.70 |
P/S ratio (TTM) P/S ratio | 1.55 |
P/B ratio (TTM) P/B ratio | 0.79 |
Revenue growth (TTM) Revenue growth | -17.95% |
Revenue (TTM) Revenue | $711.40m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a OPKO Health, Inc. forecast:
6 Analysts have issued a OPKO Health, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 711 711 |
18%
18%
|
|
Gross Profit | 95 95 |
61%
61%
|
|
EBITDA | -209 -209 |
393%
393%
|
EBIT (Operating Income) EBIT | -310 -310 |
109%
109%
|
Net Profit | -134 -134 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the following segments: Diagnostics, Pharmaceuticals, and Corporate. The Diagnostics segment include clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes comprises pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Head office | United States |
CEO | Phillip Frost |
Employees | 3,930 |
Founded | 1991 |
Website | www.opko.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.